Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Current Deferred Revenue: 2009-2024

Historic Current Deferred Revenue for Cytokinetics (CYTK) over the last 8 years, with Dec 2024 value amounting to $52.4 million.

  • Cytokinetics' Current Deferred Revenue was N/A to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year change of. This contributed to the annual value of $52.4 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Cytokinetics reported Current Deferred Revenue of $52.4 million as of FY2024, which was up 447.12% from $9.6 million recorded in FY2017.
  • Cytokinetics' Current Deferred Revenue's 5-year high stood at $52.4 million during FY2024, with a 5-year trough of $52.4 million in FY2024.
  • In the last 1 years, Cytokinetics' Current Deferred Revenue had a median value of $52.4 million in 2024 and averaged $52.4 million.